|

Intraoperative Molecular Imaging Using ICG for Head and Neck Tumors

RECRUITINGPhase 2Sponsored by Medical University of South Carolina
Actively Recruiting
PhasePhase 2
SponsorMedical University of South Carolina
Started2026-06-15
Est. completion2028-04-07
Eligibility
Age18 Years+
Healthy vol.Accepted
Locations1 site

Summary

This study is for adult patients with head and neck cancer who are at risk of recurrence. The purpose of this study is to evaluate whether the use of Indocyanine Green (ICG) dye allows for better identification of tumor tissue during surgical procedures. Participation will include standard of care visits along with administration of ICG dye and imaging during surgery. Participation in this study will last approximately 6 weeks.

Eligibility

Age: 18 Years+Healthy volunteers accepted
Inclusion Criteria:

1. Adult subjects at least 18 years of age.
2. Subjects presenting with squamous cell carcinoma of mucosal origin and are at risk for recurrence.
3. Good operative candidate as determined by the treating physician and/or multidisciplinary team.
4. Subject capable of giving informed consent and participating in the process of consent.
5. A WOCBP must be willing and able to use highly effective contraception from the time of informed consent throughout the study period. Acceptable forms of birth control include hormonal contraceptives (such as birth control pills, skin patch, vaginal ring, injection, and/or implant), intrauterine devices (IUDs), and barrier devices (such as condoms, diaphragm, cervical cap, and sponge).

Exclusion Criteria:

1. Pregnant or breastfeeding, or expecting to conceive within the projected duration of the study.
2. A WOCBP who has had a positive urine or serum pregnancy test at the time of screening unless:

   1. they are menopausal defined by not having a menstrual cycle within the last 12 consecutive months or
   2. they have had a hysterectomy.
3. Known allergy to iodides or shellfish.
4. Inadequate organ function at time of screening as defined below:

   a. Hepatic
   1. Total bilirubin \>2 x IULN. Participants with a history of Gilbert's disease must have total bilirubin \<3mg/dL.
   2. AST (SGOT) and ALT (SPGT) \>3 x IULN.
5. Currently incarcerated individuals

Conditions3

CancerMargin AssessmentSquamous Cell Carcinoma Head and Neck Cancer (HNSCC)

Interventions1

Locations1 site

Medical University of South Carolina Hollings Cancer Center
Charleston, South Carolina, 29425
HCC Clinical Trials Office843-792-9321hcc-clinical-trials@musc.edu

Browse More Trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.